greeksoup/ stock research
Stock research / United States / Funds / Novo Holdings A/s

Novo Holdings A/s

CIK 1388325 · latest 13F filed 14 August 2026 · Read the filing on EDGAR

Novo Holdings A/s reported 25 US-listed holdings worth $1.72 billion in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Edgewise Therapeutics Inc. (12.6%), ASML Holding N.V. (11.0%) and Hemab Therapeutics Hldgs Inc. (8.9%). Against the quarter before, it opened 6 positions, added to 2, trimmed 8 and sold out of 3.

Filed before as Novo Holdings A/S.

Reported holdings$1.72B+39.5% on Q1 2026
Positions25+3 on Q1 2026
The largest ten73.5%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
Where the money is
OpenedHeldTrimmed
EWTX12.6%ASML11.0%COAG8.9%BN8.7%MPLT7.7%MIRM7.6%AVLN7.4%CRM3.6%AVBP3.0%ELVN2.9%CRNX2.9%PHVS2.8%FND2.7%PCVX11 more15.4%

The 14 largest of its 25 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.

Reported holdings, quarter by quarter
Q3 2024: $2.01 billion in 37 positions$2.01BQ3 24Q4 2024: $1.65 billion in 34 positions$1.65BQ4 24Q1 2025: $1.31 billion in 31 positions$1.31BQ1 25Q2 2025: $1.42 billion in 29 positions$1.42BQ2 25Q3 2025: $1.55 billion in 27 positions$1.55BQ3 25Q4 2025: $1.29 billion in 24 positions$1.29BQ4 25Q1 2026: $1.23 billion in 22 positions$1.23BQ1 26Q2 2026: $1.72 billion in 25 positions$1.72BQ2 26

What the fund reported holding at each quarter's end; hover a bar for the number of positions

What it did on the quarter

Opened 6Added 2Held 9Trimmed 8Sold out 3
Opened: 6Added: 2Held: 9Trimmed: 8Sold out: 3

Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held

Opened 6

  1. Hemab Therapeutics Hldgs Inc. COAG$153.6 million
  2. Avalyn Pharma Inc. AVLN$127.8 million
  3. Floor & Decor Holdings, Inc. FND$47.3 million
  4. Alumis Inc. ALMS$31.0 million
  5. Dyne Therapeutics Inc. DYN$21.3 million
  6. Insmed Inc. INSM$12.9 million

Added to 2

  1. Viridian Therapeutics Inc. VRDN+135,000 shares · +7%
  2. Bridgebio Oncology Therapeutics Ord BBOT+64,077 shares · +3%

Trimmed 8

  1. Mirum Pharmaceuticals Inc. MIRM-200,000 shares · -15%
  2. Arrivent Biopharma Inc. AVBP-442,142 shares · -23%
  3. Enliven Therapeutics Inc. ELVN-280,000 shares · -22%
  4. Pharvaris N V PHVS-350,000 shares · -20%
  5. Crinetics Pharmaceuticals in CRNX-230,000 shares · -15%
  6. Celldex Therapeutics Inc. CLDX-175,000 shares · -15%
  7. 4D Molecular Therapeutics in FDMT-401,559 shares · -11%
  8. Vaxcyte Inc. PCVX-60,000 shares · -7%

Sold out of 3

  1. Apogee Therapeutics Inc. APGE$37.9 million last quarter
  2. Biomarin Pharmaceutical Inc. BMRN$37.3 million last quarter
  3. Valneva SE VALN$6.6 million last quarter

What it holds

CompanySharesValueOf its bookChange in shares
Edgewise Therapeutics Inc. EWTX5,350,000$217.4 million12.62%no change
ASML Holding N.V. ASML94,946$188.9 million10.97%no change
Hemab Therapeutics Hldgs Inc. COAG4,180,550$153.6 million8.92%new
Brookfield Corporation BN3,496,245$149.5 million8.68%no change
Maplight Therapeutics Inc. MPLT3,686,622$132.1 million7.67%no change
Mirum Pharmaceuticals Inc. MIRM1,125,000$131.7 million7.65%-200,000
Avalyn Pharma Inc. AVLN3,883,289$127.8 million7.42%new
Salesforce, Inc. CRM393,187$61.6 million3.58%no change
Arrivent Biopharma Inc. AVBP1,500,000$52.1 million3.03%-442,142
Enliven Therapeutics Inc. ELVN1,000,000$50.8 million2.95%-280,000
Crinetics Pharmaceuticals in CRNX1,320,000$49.4 million2.87%-230,000
Pharvaris N V PHVS1,400,000$48.4 million2.81%-350,000
Floor & Decor Holdings, Inc. FND797,000$47.3 million2.75%new
Vaxcyte Inc. PCVX800,000$46.5 million2.70%-60,000
4D Molecular Therapeutics in FDMT3,249,178$43.2 million2.51%-401,559
Viridian Therapeutics Inc. VRDN2,135,000$39.2 million2.28%+135,000
Celldex Therapeutics Inc. CLDX1,025,000$38.1 million2.21%-175,000
Alumis Inc. ALMS1,100,000$31.0 million1.80%new
Xenon Pharmaceuticals Inc. XENE485,438$29.3 million1.70%no change
Alibaba Group Holding Limited BABA257,327$24.7 million1.43%no change
Dyne Therapeutics Inc. DYN960,394$21.3 million1.24%new
Bridgebio Oncology Therapeutics Ord BBOT2,250,000$17.1 million1.00%+64,077
Insmed Inc. INSM120,723$12.9 million0.75%new
Marqeta Inc MQ441,558$7.2 million0.42%no change
Lanzatech Global Inc. LNZA158,148$1.1 million0.06%no change
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.
Read moreChange is shares against its 13F for the quarter before; the 3 it sold out of are in the box above.